[ESMO 2026] Vaxcell-Bio Therapeutics: "CAR-MIL Shows 100% Survival in Animal Tests, Compared with J&J's Carvykti"
Predicted impact: Low
Preclinical animal trial data at a conference; early-stage and small.
Vaxcell-Bio Therapeutics박셀바이오
323990 · KOSDAQ · ₩323990 · 박셀바이오
₩3,965▼ ₩5 (0.13%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −58.44%
- Market cap
- ₩92B
- Enterprise value
- ₩79B
- P/E
- —
- P/B
- 1.7×
- Dividend yield
- 0.0%
- ROE
- −28.0%
- Net margin
- −229.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−65.6% from the high
₩3,350Today: ₩3,920 – ₩4,070₩11,520
Returns
- 1W−6.9%
- 1M−5.8%
- 3M+3.1%
- 6M−48.3%
- YTD−60.3%
- 1Y−58.4%
- Volume today
- 44,468
- 0.6× the 20-day average
- Traded today
- ₩177M
- Listed shares
- 23,257,345
- EPS (12 months)
- −₩641
- Earnings yield −16.2%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 38 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Positive animal-test headline from a conference presentation, but still early-stage. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-5.4% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Vaxcell-Bio Therapeutics stock overview
Vaxcell-Bio Therapeutics (박셀바이오, KRX: 323990) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean biotech focused on developing anticancer immunotherapies, founded in 2010. Its shares closed at ₩3,965 on Oct 27, 2026, down 0.13% on the day, giving it a market value of ₩92B.
Key facts
- Market cap
- ₩92B
- Sector
- Biotech & Pharma
- Latest price change
- −0.13%
- As of
- Oct 27, 2026
- Main business
- The company is a Korean biotech focused on developing anticancer immunotherapies, founded in 2010.
Quick answers about Vaxcell-Bio Therapeutics
- What does Vaxcell-Bio Therapeutics do?
- The company is a Korean biotech focused on developing anticancer immunotherapies, founded in 2010. Its pipeline includes Vax-NK cell therapy (natural killer cells) and Vax-CAR cell therapies, small-molecule targeted cancer drugs, and antibody and drug-delivery platforms. It also sells veterinary immunostimulant products for companion animals, including Vaxleukin-15 and Goldmun, and runs a pharmaceutical wholesale distribution business.
- What is the market cap of Vaxcell-Bio Therapeutics?
- The market capitalisation of Vaxcell-Bio Therapeutics was ₩92B at the close on Oct 27, 2026.
- Who are the largest shareholders of Vaxcell-Bio Therapeutics?
- According to the latest official filings, the largest reported holders are Lee Je-jung (9.22%, as of Mar 27, 2026); Lee Jun-haeng (3.83%, as of Jun 24, 2025); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (1.24%, as of Jul 31, 2026).
- When is the next earnings report from Vaxcell-Bio Therapeutics?
- Korean companies rarely announce results dates in advance. Based on when Vaxcell-Bio Therapeutics filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.
- Does the National Pension Service own Vaxcell-Bio Therapeutics?
- Yes. The National Pension Service held 0.07% of Vaxcell-Bio Therapeutics shares as of Dec 31, 2024.
Company profile
The company is a Korean biotech focused on developing anticancer immunotherapies, founded in 2010. Its pipeline includes Vax-NK cell therapy (natural killer cells) and Vax-CAR cell therapies, small-molecule targeted cancer drugs, and antibody and drug-delivery platforms. It also sells veterinary immunostimulant products for companion animals, including Vaxleukin-15 and Goldmun, and runs a pharmaceutical wholesale distribution business.
Written by AI from the company's latest annual report.
- Korean name
- 박셀바이오
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 이제중 (단독 대표이사)
- Founded
- Feb 2010
- Listed
- Sep 2020
- Listed shares
- 23,257,345
- Fiscal year ends
- Month 12
- Website
- www.vaxcell-bio.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Theragen Bio Presents Poster on CAR-MIL Therapy for Multiple Myeloma at ESMO
Predicted impact: Low
Conference poster presentation on early-stage therapy research, a routine update.
Recent filings
See all- Added attachment: Half-year report (Jun 2026)Aug 14, 2026
- Investor relations (IR) eventMay 18, 2026
- Quarterly report (Mar 2026)May 15, 2026
- Insider shareholding reportMar 27, 2026
- Insider shareholding reportMar 27, 2026
Titles in Korean until English translations are added.
Also known as: Vaxcell-Bio Therapeutics / 박셀바이오 / 323990 / KRX:323990
Source: KRX statistical information